{"links":{"feed":"https://www.erudio.com/reports/keyvibe-008-nct05224141/feed.json","html":"https://www.erudio.com/reports/keyvibe-008-nct05224141","json":"https://www.erudio.com/reports/keyvibe-008-nct05224141.json","markdown":"https://www.erudio.com/reports/keyvibe-008-nct05224141.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"keyvibe-008-nct05224141"}},"request":"https://www.erudio.com/contact?report=keyvibe-008-nct05224141"},"offer":{"cited_clinicians":11,"cited_commentary_sources":17,"verified_hcp_statements":83,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":12},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"keyvibe-008-nct05224141"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=keyvibe-008-nct05224141","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/keyvibe-008-nct05224141","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 83 verified statements · 46 from 11 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-15T20:21:51.863015Z","notify_subscribers":true,"status":"updated","summary":"Replaces version 1.0.0: 10 findings, 5 of them beyond the trial population (was 10, 2 of them), 83 verified statements (was 83) from 21 sources (was 21). Now beyond the trial population: Clinicians favor adapting and sequencing standard therapy in selected unwell patients; One speaker finds choosing between established first-line regimens difficult."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":14,"no_commentary_found":0},"aspects":[{"claim_count":10,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":7,"title":"Primary endpoint: Overall Survival (OS)"},{"claim_count":2,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":2,"title":"Secondary endpoints"},{"claim_count":8,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":2,"title":"Population and setting"},{"claim_count":6,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":3,"title":"The comparison"},{"claim_count":10,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":9,"title":"Safety and tolerability"},{"claim_count":7,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":6,"title":"Design and conduct"},{"claim_count":4,"coverage":"discussed","id":"A1","source_count":1,"title":"Whether pembrolizumab or toxicity-related exposure explains the combination's outcome"},{"claim_count":5,"coverage":"discussed","id":"A2","source_count":3,"title":"Treatment transition, continued access and historical referrals"},{"claim_count":15,"coverage":"discussed","id":"A3","source_count":7,"title":"Evidence thresholds, enrollment ethics and program-level implications"},{"claim_count":3,"coverage":"discussed","id":"A4","source_count":3,"title":"Cross-program TIGIT safety interpretations"},{"claim_count":3,"coverage":"discussed","id":"A5","source_count":3,"title":"Reporting an unsuccessful study and sustaining research"},{"claim_count":9,"coverage":"discussed","id":"A6","source_count":1,"title":"Routine-care adaptation, supportive care and immunotherapy access"},{"claim_count":8,"coverage":"discussed","id":"A7","source_count":2,"title":"First-line SCLC alternatives and the rationale for the atezolizumab comparator"},{"claim_count":13,"coverage":"discussed","id":"A8","source_count":2,"title":"Molecular-subtype selection for first-line immunotherapy"}],"counts":{"beyond_population_findings":2,"beyond_population_statements":18,"cited_clinicians":11,"cited_clinicians_by_role":{"physician":3,"physician, Medical oncology":8},"cited_physicians":11,"cited_sources":21,"claims_by_expression_type":{"comparison":4,"experience":3,"interpretation":21,"opinion":15,"primary_context":16,"question":7,"restatement":9,"uncertainty":3,"unspecified":5},"claims_by_kind":{"protocol_statement":11,"publication_statement":4,"source_observation":68},"clinician_statements":46,"evidence_units":75,"findings":10,"organisational_accounts":3,"people_cited":16,"people_identity_verified":12,"people_total":16,"screened_sources":44,"verified_claims":83},"findings_index":[{"cited_clinicians":3,"id":"F1","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":2,"views":2},"limitations":3,"links":{"context":2,"support":7},"ma_question":true,"named_voices":3,"passages":7,"sources":2,"sources_by_kind":{"commentary":1,"publication":1}},"title":"Clinicians debate whether pembrolizumab itself explains the combination's outcome","evidence_line":"6 statements from 3 speakers in 2 sources"},{"cited_clinicians":4,"id":"F2","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":7,"views":7},"limitations":3,"links":{"context":3,"support":15},"ma_question":true,"named_voices":7,"passages":13,"sources":9,"sources_by_kind":{"commentary":8,"publication":1}},"title":"Clinicians read KEYVIBE-008 as an unsuccessful combination with added toxicity","evidence_line":"14 statements from 7 speakers in 9 sources"},{"cited_clinicians":2,"id":"F3","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":2,"views":4},"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":4,"passages":8,"sources":4,"sources_by_kind":{"commentary":2,"media":1,"registry":1}},"title":"One X account questions the comparator logic; one clinician questions the supporting evidence","evidence_line":"8 statements from 4 speakers in 4 sources, 1 of them a podcast or video"},{"cited_clinicians":0,"id":"F4","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":6,"views":0},"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":1,"passages":5,"sources":5,"sources_by_kind":{"commentary":3,"registry":2}},"title":"A trial-network account emphasizes referrals; relayed company statements describe a treatment-transition option","evidence_line":"7 statements from 1 speaker in 5 sources"},{"cited_clinicians":1,"id":"F5","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":3},"limitations":2,"links":{"context":0,"support":4},"ma_question":true,"named_voices":2,"passages":4,"sources":4,"sources_by_kind":{"commentary":3,"registry":1}},"title":"One clinician, described in the source as an author of the results, values rigorous reporting","evidence_line":"4 statements from 2 speakers in 4 sources"},{"cited_clinicians":0,"id":"F7","structure":{"claims":4,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":1,"views":1},"limitations":3,"links":{"context":1,"support":6},"ma_question":true,"named_voices":1,"passages":7,"sources":4,"sources_by_kind":{"commentary":3,"publication":1}},"title":"One X account challenges benign TIGIT safety; another ranks GALAXIES more favorably","evidence_line":"4 statements from 1 speaker in 4 sources"},{"cited_clinicians":3,"id":"F8","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":2,"questions":0,"restated":0,"views":6},"limitations":3,"links":{"context":0,"support":12},"ma_question":true,"named_voices":3,"passages":6,"sources":1,"sources_by_kind":{"media":1}},"title":"Clinicians discuss small-cell treatment despite cytopenias, with conditional adjustments and support; one addresses access-dependent immunotherapy timing and disease-related liver dysfunction.","evidence_line":"9 statements from 3 speakers in 1 source, a podcast or video"},{"cited_clinicians":2,"id":"F9","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":3,"views":4},"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":2,"passages":7,"sources":3,"sources_by_kind":{"commentary":1,"media":1,"registry":1}},"title":"One speaker finds choosing between established first-line regimens difficult","evidence_line":"8 statements from 2 speakers in 3 sources, 1 of them a podcast or video"},{"cited_clinicians":5,"id":"F6","population":"beyond","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":4,"restated":1,"views":2},"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":5,"passages":6,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"Clinicians ask whether anti-TIGIT enrollment and development should continue","evidence_line":"7 statements from 5 speakers in 5 sources, 1 of them a podcast or video"},{"cited_clinicians":1,"id":"F10","population":"beyond","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":0,"views":9},"limitations":4,"links":{"context":0,"support":13},"ma_question":true,"named_voices":1,"passages":5,"sources":1,"sources_by_kind":{"media":1}},"title":"One speaker asks whether inflamed or YAP1-positive data are ready to justify a phenotype-selected immunotherapy trial","evidence_line":"12 statements from 1 speaker in 1 source, a podcast or video"}],"open_question":{"basis":"From finding F1 (6 statements from 3 speakers in 2 sources)","cited_claim_ids":["claim-0f2d8132f3235346ac4e","claim-d5330c69a7201f281f0c","claim-fe2c09fa7d67a9fe3a52","claim-1878f2f44813d64225b3","claim-587239f2d2b029b1cfd4","claim-bfd6a6adfcbcc9c2c370"],"finding_ids":["F1"],"question":"In KEYVIBE-008 for first-line extensive-stage small-cell lung cancer, what do clinicians say could distinguish pembrolizumab efficacy from toxicity-related shortening of pembrolizumab exposure as possible explanations for overall-survival findings with vibostolimab–pembrolizumab plus chemotherapy versus atezolizumab plus chemotherapy?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Clinicians debate whether pembrolizumab itself explains the combination's outcome"},{"id":"section-2","level":2,"title":"Clinicians read KEYVIBE-008 as an unsuccessful combination with added toxicity"},{"id":"section-3","level":2,"title":"One X account questions the comparator logic; one clinician questions the supporting evidence"},{"id":"section-4","level":2,"title":"A trial-network account emphasizes referrals; relayed company statements describe a treatment-transition option"},{"id":"section-5","level":2,"title":"One clinician, described in the source as an author of the results, values rigorous reporting"},{"id":"section-6","level":2,"title":"One X account challenges benign TIGIT safety; another ranks GALAXIES more favorably"},{"id":"section-7","level":2,"title":"Clinicians favor adapting and sequencing standard therapy in selected unwell patients"},{"id":"section-8","level":2,"title":"One speaker finds regimen choice patient-dependent; another asks when substantial SCLC progress will arrive"},{"id":"section-9","level":2,"title":"Beyond the trial population"},{"id":"section-10","level":3,"title":"Clinicians ask whether anti-TIGIT enrollment and development should continue"},{"id":"section-11","level":3,"title":"One speaker asks whether inflamed or YAP1-positive tumors can guide prospective immunotherapy studies"},{"id":"section-12","level":3,"title":"Scope and coverage"},{"id":"section-13","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":7},{"id":"F7","shared_claims":1}],"id":"T1","label":"Primary endpoint: Overall Survival (OS)"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F5","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F4","shared_claims":1},{"id":"F8","shared_claims":6},{"id":"F9","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F8","shared_claims":1},{"id":"F9","shared_claims":3}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":6},{"id":"F7","shared_claims":3}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-15T20:21:51.863015Z","edition_number":2,"previous_run_id":"55d241c6-faad-4377-9a2f-5062dfc29bd1","previous_version":"1.0.0","product_contract":"hcp-commentary-1","published_at":"2026-11-15T20:51:27Z","record_hash":"0517b3a1bd9c32c0a267c5b8f62d6e905389843ff40fc5d245c9bc2b93f24d0c","release_hash":"e1c9f3a60fa52841d657515551a268b516a9d7cc04cdaf5e30a45f108209d725","report_id":"erudio-nct05224141","run_id":"22d266d9-bee1-42e9-9529-e4a130f973f6","schema_version":"5.0","slug":"keyvibe-008-nct05224141","version":"1.1.0","version_reason":"material_change"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"KEYVIBE-008 leads a medical oncologist to question whether pembrolizumab could be worse than atezolizumab if TIGIT blockade adds no benefit. A physician doubts that interpretation and relays speculation that toxicity-related discontinuation may have shortened pembrolizumab exposure; neither explanation is demonstrated. Another medical oncologist criticizes the combination for adding toxicity, but these negative assessments do not establish that all anti-TIGIT combinations lack benefit.","examples":[],"meta_description":"44 sources screened · 83 verified statements (46 from clinicians verified by NPI or staff page) from 21 sources · 10 findings. Updated Nov 15, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-15T20:51:27Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":44},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on long-term survival expectations with first-line chemoimmunotherapy versus chemotherapy in extensive-stage small-cell lung cancer; a view on dual checkpoint blockade as first-line treatment for extensive-stage small cell lung cancer; a view on survival-endpoint limitations when interpreting durable responses to first-line chemoimmunotherapy in extensive-stage small-cell lung cancer; a view on TIGIT inhibition as a treatment strategy in first-line extensive-stage small cell lung cancer.","48 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 28 sources about other trials or topics are not included.","The sources reviewed provide qualitative views, not a representative sample of HCP opinion or a measure of consensus. Reposts and repeated company quotations can amplify one original statement.","Discussion that does not name the trial, uses other terminology or appears outside the reviewed channels may be missing.","Some named accounts do not have an established clinical role in the sources reviewed. Their statements should not be treated as verified HCP assessments.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The interim combination comparison does not isolate pembrolizumab, vibostolimab or toxicity-related exposure as the cause of the outcome. The proposed explanations remain conditional or speculative.","Cross-study safety rankings and historical survival comparisons are not head-to-head evidence.","Historical recruitment communications do not establish current availability. Offering atezolizumab does not establish that a patient received it, and continued study access had specific benefit and access conditions.","The amended protocol stopped further efficacy and survival follow-up and restricted further patient-reported-outcome analysis. A speaker's description of quality-of-life coverage is not reconciled with the amended registry's reporting restriction.","The molecular-subtype discussion is exploratory, retrospective and limited to the first-line analyses discussed. It does not establish a validated predictive marker for MK-7684A.","Product information was incomplete for the co-formulation and saline placebo, so the report does not provide an independent label-status assessment."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":0,"publication":2,"registry":2,"regulatory":0,"x_thread":15,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":17,"context":2,"methods":2},"count":21,"evidence_window":{"end":"2026-10-21","start":"2022-03-30"},"retrieval_snapshot":"2026-11-15T14:21:59.577630Z","timeline":[{"count":1,"week":"2022-W13"},{"count":1,"week":"2022-W17"},{"count":1,"week":"2022-W32"},{"count":1,"week":"2022-W42"},{"count":1,"week":"2024-W01"},{"count":6,"week":"2024-W32"},{"count":2,"week":"2024-W37"},{"count":1,"week":"2024-W45"},{"count":1,"week":"2024-W51"},{"count":1,"week":"2025-W05"},{"count":2,"week":"2026-W43"}],"undated_sources":4},"quote_policies":[{"id":"clinicaltrials:NCT05224141:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05224141:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05224141:context","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05224141:sap:1","quote_policy":"short_quote_link_out"},{"id":"pubmed:39230120","quote_policy":"no_derivatives"},{"id":"pubmed:42900351","quote_policy":"short_quote_link_out"},{"id":"openfda:4f850eb2-3542-43a0-90e8-bb37fa05cf15:20261109","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ryo5z53ggbjijxq7nd6ftqjx-3myu32z4vpk2x","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7518642633679011840","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1489601948089126914:626dee59-a795-47df-beff-274167429bec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1509071242355163137:52811fd9-25e1-40a5-a10d-c74061d99408","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1524296623639126017:0bb19820-ca82-40ad-8220-f6f04330cb7b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1556650231747469314:c57c10a2-d4dc-4175-a391-cd239550f3ba","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1583446371654602752:1ea7e87d-039a-463b-92ee-a39d48914dc2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821498241705504835:f1d0f0fe-8092-4f53-9ca7-cd1468c2af44","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821498616566976696:1b141f13-0f6c-4387-82c0-f22aa04c3513","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821498955856810214:d2453a07-9a50-4f50-91f4-c1e6e40ab283","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821499000102539471:420a2a4a-eabb-4001-b20b-d050efdf97e4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821500154240704932:556e09f9-c281-490c-97a8-dc899c52b82e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821501121493344291:2f0146f4-dbfe-49a4-875f-84575e58e633","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821511306190668260:b415c86c-15e7-48cb-9594-a7a9be0ed351","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821517636749975963:7111022d-cfa4-49d5-b9ee-fc063413da36","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821521759239086388:078a53b4-bd71-4da9-9167-1f6c9a132a56","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821543798536540631:f08acaa4-5199-4a02-a3a9-2d19b7045a0f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821564043716444329:756bc879-ce39-4378-b1d5-08f9ff2dc1bf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821769657453318480:ba06505d-0981-447a-814a-cc693dea2e61","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821843513954164779:775303bf-1052-4a7e-803f-d1bbccaf0573","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821860334258315275:cbbd15a6-0d95-44ec-b24f-8765b6a9b076","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821862733785989448:a071f173-3106-4efc-bb1e-5fb5595c89d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821868355101319675:189ecd1d-f250-4047-8111-32151f4ac64d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821878668773220671:7d5c6e19-4d82-4615-bac6-9e3b21047603","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821924942427885943:6bcae422-06a8-4d31-ab12-d652543fbda5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1822241947253199150:c564b7bc-8a7f-4829-992e-d7ac78c0fe2b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1823011811051831709:84eacfbe-cd96-49a8-b1a8-a7dd214560d1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1823419860497404357:fa42a1bb-0202-4e58-babb-aade70c3eec6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1824826068370325935:4e557e7f-5c65-4a87-8774-adc9ee5d4676","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1826001468052193523:bbb505b4-dddb-436e-bcb9-efb4dde21f62","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1826381771073544557:94d7b5c5-414b-4cc8-9a24-5b2847684176","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1827269723890798967:efe9fb95-86cc-434f-97a8-c22820aa9512","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834906344769323270:7ab1828e-27bf-4f90-a45f-231bb96ee878","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835379477792141371:d685b5db-b2cb-4de1-8c79-ef8bdb0f4bda","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1842161418772124078:56c7d183-f607-4245-ade0-890430bbccf8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1842164709639827563:9a43b2bf-1d10-46ed-bb2c-61a3189785e9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1854948245828780501:2ac5c2d0-f451-4fed-90e3-6ced338499b1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1855690640300097957:4e2ee753-df3f-4ef3-b48c-b67ab5a8ec5c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1860360430033719441:cd11e1b8-c0b6-423e-91f2-893ce3a2e1e5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1869130831022993802:54fd61dd-c704-4c87-8975-3e5bfa6a0391","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1885387045301833940:72ca8643-b8a7-49ea-acf0-ee7f95dd739c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1978471945508446282:91fced3a-55d1-4981-9f0d-e656dac56607","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112879034514235557:13511d0b-7be1-4074-a9ca-c476d973f73d","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:5iyMRDUMjtQ","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":41,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":44},"count":44,"evidence_window":{"end":"2026-10-27","start":"2022-02-04"},"retrieval_snapshot":"2026-11-15T14:21:59.577630Z","timeline":[{"count":1,"week":"2022-W05"},{"count":1,"week":"2022-W13"},{"count":1,"week":"2022-W17"},{"count":1,"week":"2022-W19"},{"count":1,"week":"2022-W22"},{"count":1,"week":"2022-W32"},{"count":1,"week":"2022-W42"},{"count":1,"week":"2024-W01"},{"count":19,"week":"2024-W32"},{"count":3,"week":"2024-W33"},{"count":3,"week":"2024-W34"},{"count":2,"week":"2024-W37"},{"count":2,"week":"2024-W40"},{"count":2,"week":"2024-W45"},{"count":1,"week":"2024-W47"},{"count":1,"week":"2024-W51"},{"count":1,"week":"2025-W05"},{"count":1,"week":"2025-W42"},{"count":2,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":2,"other":0,"podcast":0,"publication":4,"registry":12,"regulatory":0,"x_thread":35,"x_video":0,"youtube":30}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: pembrolizumab/vibostolimab co-formulation","status":"unmapped"},{"reason":"Unmapped registry intervention: saline placebo","status":"unmapped"},{"reason":"Unmapped registry intervention: etoposide","status":"unmapped"},{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"},{"brand_names":["Tecentriq"],"label":"atezolizumab","slug":"atezolizumab"},{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"}],"indications":[{"reason":"Unmapped registry condition: Small Cell Lung Carcinoma","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Small cell lung cancer","slug":"small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"KEYVIBE-008","aliases":["KEYVIBE-008","MK-7684A-008/KEYVIBE-008","Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008)"],"brief_title":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Small Cell Lung Carcinoma"],"display_condition":"first-line extensive-stage small cell lung cancer","display_interventions":[["MK-7684A"]],"enrollment":{"count":460,"type":"ACTUAL"},"interventions":[{"name":"Pembrolizumab/Vibostolimab Co-Formulation","synonyms":["MK-7684A"],"type":"BIOLOGICAL"},{"name":"Saline placebo","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Etoposide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Cisplatin","synonyms":["PLATINOL-AQ®"],"type":"DRUG"},{"name":"Atezolizumab","synonyms":["TECENTRIQ®"],"type":"BIOLOGICAL"},{"name":"Carboplatin","synonyms":["PARAPLATIN®"],"type":"DRUG"}],"nct_id":"NCT05224141","official_title":"A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008)","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2024-06-04","type":"ACTUAL"},"primary_endpoints":[{"description":"Overall Survival (OS) was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. OS was calculated using the nonparametric Kaplan-Meier method for censored data.","measure":"Overall Survival (OS)","timeFrame":"Up to approximately 25 months"}],"registered_date":{"date":"2022-02-04","type":"ACTUAL"},"registry_last_updated":"2025-07-08","registry_url":"https://clinicaltrials.gov/study/NCT05224141","short_name":"KEYVIBE-008","short_name_basis":"canonical_name","sponsor":"Merck Sharp & Dohme LLC","start_date":{"date":"2022-03-24","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"7684A-008","type":"sponsor_study_id"},{"domain":"MSD","id":"MK-7684A-008","type":"other"},{"domain":"MSD","id":"KEYVIBE-008","type":"other"},{"domain":"jRCT","id":"jRCT2021220008","type":"registry"},{"domain":"EU CT","id":"2023-503517-30-00","type":"registry"},{"domain":"UTN","id":"U1111-1287-4436","type":"registry"},{"id":"2021-005034-42","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}